Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of protein minimizes the risk of inflammation/thrombosis, while the formulation increases drug absorption, especially in diabetic patients.
Abluminal Reservoir Technology: Controlled and targeted drug elution as a result of Abluminal Reservoir Technology.
Amphilimus™ Formulation: Optimal efficacy achieved through shared drug delivery and improved bioavailability due to the patented Amphilimus™ formulation, which is a combination of Sirolimus plus Fatty Acid.
Bio Inducer Surface: Proven bio and hemocompatibility made possible by the Bio Inducer Surface coating, which accelerates the rate of endothelialization and reduces thrombogenicity.